MedTrace Logo

Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

NCT03838796 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 297

Last updated 2022-08-02

No results posted yet for this study

Summary

The purpose of the study is to observe the effect of Lenvatinib Combined With TACE in preventing the recurrence in high-risk patients with hepatocellular carcinoma.

Conditions

Interventions

DRUG

lenvatinib

for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po

PROCEDURE

TACE

The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Lunxiu Qin, MD · Department of general surgery, Huashan hospital, Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2022-06-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03838796 on ClinicalTrials.gov